ENTITY

Insilico Medicine (3696 HK)

69
Analysis
Health Care • Hong Kong
Insilico Medicine is an artificial intelligence (AI)-based biotechnology company that applies AI solutions to drug discovery and development, leveraging its proprietary Pharma.AI platform to identify and design early-stage drug candidates. The company develops novel drugs for various diseases, including cancer, fibrosis, immunity, and central nervous system disorders, and predicts clinical trial outcomes. Insilico Medicine was founded in 2014 and is headquartered in New Territories, Hong Kong.
more
•09 Jan 2026 15:23•Syndicated

CX Daily: China’s AI Toy Story

In Depth: China’s AI Toy Story In Depth: The Downfall of the Cyber Kingpin Behind the $15 Billion Bitcoin Seizure Standard Chartered Forecasts...

Logo
209 Views
Share
x